Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viatris Reveals Generic Rybelsus Candidate As Part Of Continued Complex Push

Eight Complex Programs Are At Various Stages Of Development

Executive Summary

Recently-formed Viatris is looking to build on the success of several high-margin complex generics launches, including versions of Advair and Copaxone, by developing further candidates, including rivals to Novo Nordisk’s Rybelsus (semaglutide) and Victoza (liraglutide).

You may also be interested in...



What Does Viatris’ Trio Of Attacks On US Semaglutide Mean For Wegovy Generics?

Viatris has failed in its attempt to begin proceedings to overturn two key semaglutide patents in the US, while succeeding on another, as part of its bid to gain early entry with its proposed generic version of Novo Nordisk’s renowned Wegovy. Generics Bulletin reviews the landscape.

Invega Trinza, Pentasa, and Abilify LAI Top Viatris’ First Complex Ambitions

Viatris spent a good chunk of its recent investor day updating on its complex generics ambitions, especially considering it is set to be missing biosimilars from its armory in the back half of 2022. A proposed move for the first US generic Symbicort was suggested by management.

Viatris CEO Talks Integration, Roadmap And Interchangeable Biosimilars

As CEO Michael Goettler provides an update on the progress made by Viatris in its first year as a combined company, he also offers Generics Bulletin hints as to the detailed strategy that will be unveiled at the firm’s upcoming investor day and explains how biosimilars – including interchangeable Semglee (insulin glargine) – and complex generics are important components of the firm’s future growth plans.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB150734

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel